This Month in Psychopharmacology

THIS MONTH IN
PSYCHOPHARMACOLOGY

New Long-Acting Injectable Formulation of Aripiprazole Approved
July 16, 2018

The FDA has now approved a NanoCrystal® injectable formulation of the atypical antipsychotic aripiprazole (Alkermes' Aristada Initio) for the treatment of schizophrenia in adults...

Continue reading (Members only)

Lithium Use During Pregnancy and Maternal and Infant Outcomes
July 13, 2018

Lithium is a staple and highly effective medication for the treatment of bipolar disorder; however, past data have indicated somewhat mixed data regarding the teratogenic effects of lithium use during pregnancy...

Stress and Neurodevelopment
July 11, 2018

Researchers studied 37 individuals from early childhood through adolescence and examined the impact of negative life events and negative social experiences on brain development...

Continue reading (Members only)

FDA Approves First Cannabis-Derived Medication Approved
July 3, 2018

The US Food and Drug Administration (FDA) has approved the first cannabis-based medicine to treat drug resistant childhood epilepsies...

Continue reading (Members only)

Novel Approach to Treating Posttraumatic Stress Disorder
June 27, 2018

A novel approach to the treatment of combat-related post-traumatic stress disorder (cr-PTSD) could play a significant role in helping British veterans overcome PTSD, a new Cardiff University research project suggests...

Placental Biology and Genetic Risk for Schizophrenia
June 18, 2018

In a recent study, the relationship between placenta biology and genetic risk for schizophrenia in the presence of early-life complications (ELCs) was examined...

Continue reading (Members only)

Risk of Antidepressant-Induced Weight Gain
June 15, 2018

A population-based cohort study examined the relationship between antidepressant treatment and weight gain over 10 years...

Continue reading (Members only)

Recommendations for Suicide Prevention Released
June 8, 2018

A panel of experts, as part of the National Action Alliance for Suicide Prevention, has recently published guidelines aimed at improving suicide prevention across a range of health care organizations, including primary care, emergency room, and inpatient and outpatient mental health care settings...

Proposed ICD-11 PTSD Criteria May Lead to Missed Diagnoses
June 5, 2018

A recent study examined whether changes to post-traumatic stress disorder (PTSD) diagnostic criteria in the upcoming International Classification of Diseases (ICD)-11 may affect the prevalence and identification of PTSD cases...

Continue reading (Members only)

FDA Approves First Non-Opioid to Treat Opioid Withdrawal Symptoms
May 21, 2018

The US FDA has approved the first non-opioid treatment for the relief of opioid withdrawal symptoms. The medication, lofexidine hydrochloride (trade name Lucemyra), is an oral, selective alpha-2 adrenergic receptor agonist...

Top of Page